Michelle Hassard
Nurse Practitioner · Sullivan, MONPI 1558023903
Payments from drug & device makers
Across 127 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$396
- GSK$231
- Novo Nordisk$179
- Otsuka America Pharmaceutical, Inc.$161
- Lilly USA, LLC$160
- AstraZeneca$104
- plus $934 from 22 others
What the payments were for
- Food & beverage$2,165100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $396 |
| GSK | 14 | $231 |
| Novo Nordisk | 10 | $179 |
| Otsuka America Pharmaceutical, Inc. | 8 | $161 |
| Lilly USA, LLC | 9 | $160 |
| AstraZeneca | 7 | $104 |
| Exact Sciences | 5 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Dexcom, Inc. | 3 | $72 |
| Amgen | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 4 | $60 |
| Lundbeck LLC | 3 | $59 |
| Sumitomo Pharma America, Inc. | 4 | $58 |
| Johnson & Johnson(2 entities) | 3 | $53 |
| Gilead | 3 | $52 |
| Pfizer | 3 | $46 |
| Novartis | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Merck | 2 | $32 |
| Organon | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Edwards Lifesciences | 1 | $21 |
| Abiomed | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,165 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 14 | $23,680 |
| JardianceEmpagliflozin | 16 | $11,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $11,245 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $8,176 |
| Fluvoxamine Maleate | 26 | $1,283 |
| Omeprazole | 55 | $994 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $816 |
| Famotidine | 31 | $600 |
| Simvastatin | 50 | $458 |
| Levothyroxine Sodium | 63 | $427 |
| Fenofibrate | 34 | $415 |
| Duloxetine Hcl | 34 | $398 |
| Citalopram HbrCitalopram Hydrobromide | 42 | $331 |
| Atorvastatin Calcium | 68 | $323 |
| Rosuvastatin Calcium | 37 | $318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $160 | $23,68014 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $231 | $19,42130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Sullivan
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
- Carrie Roth BettlachSaint Louis$21K
- Amanda HumbersFarmington$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.